NasdaqGM:PTGXBiotechs
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 129% One Year Surge?
Wondering whether Protagonist Therapeutics at around US$105.55 still offers value, or if most of the opportunity is already reflected in the price.
The stock has posted returns of 0.1% over the past week, 7.1% over 30 days, 21.1% year to date and 128.7% over the last year, which may have shifted how investors think about both its potential and its risks.
Recent news coverage has focused on Protagonist Therapeutics as a higher profile biotech name, with attention centered on its pipeline...